It’s in the blood: Patient-derived hematologic malignancy models in research

Hematological malignancies are cancers that begin in the cells of blood-forming tissue or in the cells of the immune system. These types of cancer, specifically, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are on the rise in the aging population globally. In this webinar, Dr. Wesa will demonstrate how patient-derived hematologic malignancy in vivo and ex vivo models can be used to advance drug development. Viewing this webinar will help you to: •Develop an understanding of a robust approach to human AML Patient-derived Xenograft (PDX) in vivo models •Learn how to select study endpoints for in vivo and ex vivo models •Learn how to advance early stage compounds through Champions’ hematologic Vitroscreen for AML, B-ALL and MCL Disease indications